| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.05. | Phio Pharmaceuticals Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762 | 240 | Newsfile | Intratumoral PH-762 has encouraging safety profile in the initial cohortEscalation to proceed to next dose concentrationMarlborough, Massachusetts--(Newsfile Corp. - May 28, 2024) - Phio Pharmaceuticals... ► Artikel lesen | |
| 23.05. | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) | 300 | Newsfile | Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology... ► Artikel lesen | |
| 20.05. | Phio Pharmaceuticals files for $100M mixed shelf | 4 | Seeking Alpha | ||
| 17.05. | Phio Pharmaceuticals files for $100M mixed securities shelf | 4 | Seeking Alpha | ||
| 17.05. | Phio Pharmaceuticals Corp. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 17.05. | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Secures New Investor | 144 | GlobeNewswire (Europe) | MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is... ► Artikel lesen | |
| 17.05. | Phio Pharmaceuticals Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study | 44 | GlobeNewswire (Europe) | -PH-762 is Phio's lead product candidate -Screening on the next cohort is on-going MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage... ► Artikel lesen | |
| 10.05. | Phio Pharmaceuticals GAAP EPS of -$0.47 | 3 | Seeking Alpha | ||
| 09.05. | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update | 123 | GlobeNewswire (Europe) | -Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 -Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio... ► Artikel lesen | |
| 09.05. | Phio Pharmaceuticals Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.05. | Phio Pharmaceuticals Corp. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 30.04. | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO) | 5 | GlobeNewswire (USA) | ||
| 22.04. | Why Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday? | 5 | Benzinga.com | ||
| 22.04. | Phio Pharmaceuticals Corp.: Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells | 36 | GlobeNewswire (Europe) | -Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma... ► Artikel lesen | |
| 16.04. | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) | 102 | GlobeNewswire (Europe) | MARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is... ► Artikel lesen | |
| 11.04. | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT) | 4 | GlobeNewswire (USA) | ||
| 03.04. | Phio Pharmaceuticals Corp.: National Spotlight Features Phio's Innovative RNAi Technology Platform | 5 | GlobeNewswire (USA) | ||
| 02.04. | Phio Pharmaceuticals GAAP EPS of -$5.20 | 2 | Seeking Alpha |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| TUI | 5.814 |
| GAMESTOP | 3.847 |
| NEL | 3.685 |
| NVIDIA | 3.678 |
| EVOTEC | 3.399 |
| BAYER | 2.598 |
| PLUG POWER | 2.161 |
| BYD | 1.941 |
| VOLKSWAGEN | 1.414 |
| DEUTSCHE LUFTHANSA | 1.314 |
| RHEINMETALL | 1.257 |
| SUPER MICRO COMPUTER | 1.178 |
| BIONTECH | 1.174 |
| DEUTSCHE TELEKOM | 1.168 |
| ALLIANZ | 1.120 |
| AIXTRON SE | 982 |
| DEUTSCHE BANK | 906 |
| SIEMENS ENERGY | 901 |
| COMMERZBANK | 860 |
| RWE | 858 |
| BASF | 840 |
| THYSSENKRUPP | 800 |
| TESLA | 777 |
| MERCEDES-BENZ | 732 |
| BARRICK GOLD | 687 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
